A Comparative Study of Human and Zebrafish Pregnane X Receptor Activities of Pesticides and Steroids Using In Vitro Reporter Gene Assays

Nicolas Creusot, Clémentine Garoche, Marina Grimaldi, Abdelhay Boulahtouf, Barbara Chiavarina, William Bourguet, and Patrick Balaguer

1 Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Institut Régional du Cancer de Montpellier (ICM), Université Montpellier, Montpellier, France, 2 Centre de Biologie Structurale (CBS), Inserm, CNRS, Université Montpellier, Montpellier, France

INTRODUCTION

The nuclear receptor pregnane X receptor (PXR) is a ligand-dependent transcription factor that regulates genes involved in xenobiotic metabolism in mammals. Many studies suggest that PXR may play a similar role in fish. The interaction of human PXR (hPXR) with a variety of structurally diverse endogenous and exogenous chemicals is well described. In contrast, little is known about the zebrafish PXR (zfPXR). In order to compare the effects of these chemicals on the PXR of these two species, we established reporter cell lines expressing either hPXR or zfPXR. Using these cellular models, we tested the hPXR and zfPXR activity of various steroids and pesticides. We provide evidence that steroids were generally stronger activators of zfPXR while pesticides were more potent on hPXR. In addition, some chemicals (econazole nitrate, mifepristone, cypermethrin) showed an antagonist effect on zfPXR, whereas no antagonist chemical has been identified for hPXR. These results confirm significant differences in the ability of chemicals to modulate zfPXR in comparison to hPXR and point out that zfPXR assays should be used instead of hPXR assays for evaluating the potential risks of chemicals on aquatic species.

Keywords: pesticides, steroids, reporter cell lines, human PXR, zebrafish PXR

INTRODUCTION

In the context of increasing exposure to environmental contaminants, the detoxification process plays a critical role in the protection of human and wildlife. To this end, the pregnane X receptor (PXR), as a nuclear receptor, is a key transcriptional factor that regulates the expression of a wide range of genes coding for metabolic enzymes (e.g. P450, GST, UGT) and transporters (e.g. MDR1, MRP, OATP2) involved in the elimination of adverse chemicals and the clearance of endogenous hormones to sustain homeostasis in mammalian species (1). Several studies also highlighted its role

Abbreviations: PXR, pregnane X receptor; hPXR, human PXR; zfPXR, zebrafish PXR; LBD, ligand binding domain; DBD, DNA binding domain; LBP, ligand binding pocket.
in bone homeostasis, inflammation, drug-drug interaction, cancer drug resistance and proliferation in humans (2). In fish, although PXR role remains unclear, recent investigations reported its involvement in the regulation of P450 genes and revealed a crosstalk between zebrafish Aryl Hydrocarbon Receptor (AhR) and PXR, suggesting a role in the detoxification of xenobiotics in addition to bile salt metabolism (3–6). Thus, modulation of fish PXR could affect their ability to eliminate adverse chemicals. In this context, it is crucial to identify environmental modulators of PXR to unravel the environmental hazard/risk implications for fish.

PXR has been cloned and functionally characterized in various species such as human, rat, polar bear, zebrafish, and frog (7). These investigations revealed marked interspecies differences in terms of ligand selectivity and specificity in parallel with high cross-species sequence divergence in the ligand binding domain (7, 8). The ligand binding pocket (LBP) of the human PXR is smooth, hydrophobic and large (~1,300 Å) allowing to be promiscuously activated by endogenous hormones and a broad number of chemically and structurally different compounds including environmental contaminants, in accordance with its role in the xenobiotic detoxification. These compounds include steroids, pesticides, alkylphenols, bisphenols plasticizers, pharmaceuticals, etc. (10–14). Besides, we have recently described the capacity of environmental pollutants to bind simultaneously to the hPXR, leading to its synergic activation (15, 16). Since X-ray crystallography of the PXR has only been reported for human, little is known regarding the structure of the PXR in other species. Nevertheless, homology models of the ligand binding domains (LBDs) of zebrafish (~1,000 Å) predicted smaller LBPs than that of hPXR (8). Despite little evidence, the fish PXR seems to be activated by less chemicals, likely because of its smaller binding pocket (7, 8, 17). In addition, homology models combined to docking studies showed that amino-acid residues involved in ligand interaction differ between species (8, 17). Altogether, these results showed that functional analysis of zebrafish PXR would be particularly useful in defining ligand specificity in terms of efficacy and potency in fish.

The aim of this study is to better characterize the cross-species differences between human and zebrafish in the modulation and the function of the PXR. To this end, we first screened a set of chemically and structurally various compounds (steroids and pesticides) using human stable reporter gene cell lines based on chimeric (Gal4-PXR) receptors. We then confirmed the zpPXR potency in a zebrafish reporter cell line. Finally, we investigated the structural basis of the differences in PXR modulation between human and fish applying homology docking models.

MATERIAL AND METHODS

Chemicals and Reagents
A list of tested chemicals is provided in the Supplementary Material (Supplementary Table 1).

Plasmids
The total zpPXR coding sequence (M1-T430) was isolated from the ZFL cells extracts by RT-PCR with primers containing XhoI and KpnI restriction enzyme sites (Supplementary Table 2). The full-length sequence of the zpPXR was then integrated in the pSG5-puromycin plasmid between XhoI and KpnI sites. Primers were then designed to amplify the ligand binding domain (LBD) of the zpPXR (M111-T430). The LBD sequence of the zpPXR was then integrated in the pSG5-Gal4(DNA-binding domain (DBD))-puromycin plasmid between XhoI and SacI enzyme restriction sites.

The PGL4.24-6xPXRE reporter plasmid (6) is a kind gift from Anke Lange and Charles Tyler. The PXRE6-TATA-luciferase-hygromycin was constructed by adding the hygromycin resistance in this plasmid.

Establishment of Stable PXR-Based Reporter Gene Cell Lines
The cell lines used in this study are listed in Supplementary Table 3. The HG5LN, HG5LN Gal4-hPXR and HG5LN Gal4-zpPXR cell lines were previously described (19). Briefly, HeLa cells stably transfected with the GAL4RE5-BGlobin-Luc-SVNeo plasmid (HG5LN cell line) (15). HG5LN cells were stably transfected with the pSG5-GAL4(DBD)-hPXR(DBD)-puro or pSG5-GAL4(DBD)-zpPXR(DBD)-puro plasmids. HG5LN Gal4-hPXR and Gal4-zpPXR cell lines were selected for their inducibility in presence of SR12813 3 µM and clotrimazole 1 µM, respectively.

The ZFL zpPXR cells were obtained by stable cotransfection of ZFL cells with the pSG5-zpPXR-puromycin and PXRE6-TATA-luciferase-hygromycin plasmids and selected for their inducibility in presence of clotrimazole 1 µM.

Cell Culture
HG5LN cells were cultured in Dulbecco’s Modified Eagle Medium: Nutrient Mixture F-12 (D-MEM/F-12) containing phenol red and 1 g/L glucose and supplemented with 5% fetal bovine serum, 100 units/mL of penicillin and 100 µg/mL of streptomycin supplemented with 1 mg/mL genetin in a 5% CO2 humidified atmosphere at 37°C. HG5LN GAL4-hPXR and GAL4-zpPXR were cultured in the same culture medium supplemented with 0.5 µg/mL puromycin.

ZFL zpPXR cells were cultured in Leibovitz’s L-15, D-MEM, Ham’s F-12 medium (D-MEM containing) medium containing 50% L-15, 35% D-MEM, and 15% F-12, 5% FCS with 0.15 g/L sodium bicarbonate, 15 mM HEPES buffer, 0.01 mg/mL insulin, 50 ng/mL EGF, 100 units/mL of penicillin, 100 µg/mL of streptomycin supplemented with 0.5 µg/mL puromycin and 0.25 mg/mL hygromycin B in a humidified atmosphere at 28°C.

Luciferase Assay
The ability of chemicals to modulate the hPXR and zpPXR was investigated in HG5LN, HG5LN-hPXR, HG5LN-zpPXR, and ZFL-zpPXR cell lines after exposure to serial dilutions of the compounds and measurement of luciferase activity. Exposure of the HG5LN cells which do not express PXR allows to check the specificity of the PXR transactivation in HG5LN-hPXR and HG5LN-zpPXR cell lines. Briefly, cells were seeded in 96-well white opaque flat bottom microplates at 0.5 X 10^4 cells per well in culture medium. After 24h of growing at 37°C (HG5LN,
After 5 min, the production of light was assessed in living cells medium containing 0.3 mM D-luciferin were added per well. After 16h of exposure, medium was removed and 50 µL of test concentration of DMSO in the well never exceeds 0.1% (v/v). zfPXR and ZFL-zfPXR that correspond to 80% of the SR12813 (HG5LN-hPXR) or 0.1 µM of clotrimazole (HG5LN-zfPXR cell line), the culture medium was removed and replaced with 100 units/mL of penicillin, 100 µg/mL of streptomycin and dextran-coated charcoal-treated fetal calf serum DCC-FCS (5%) for the ZFL-zfPXR cell line. Cells were then exposed to a concentration range of the compounds by using an automated workstation (Biomek 3000, Beckman Coulter). The final concentration of DMSO in the well never exceeds 0.1% (v/v). After 16h of exposure, medium was removed and 50 µL of test medium containing 0.3 mM D-luciferin were added per well. After 5 min, the production of light was assessed in living cells using microplate reader (MicroBeta, PerkinElmer SAS, Courtabœuf, France).

To assess antagonistic activity, cells were coexposed with serial dilutions of the tested chemicals in presence of 0.3 µM SR12813 (HG5LN-hPXR) or 0.1 µM of clotrimazole (HG5LN-zfPXR and ZFL-zfPXR) that correspond to 80% of the maximal transactivation.

**Data Modelling**
In the transactivation assay, each compound was tested at various concentrations in three independent experiments at least. For each experiment, tests were performed in quadruplicates for each concentration, and data are expressed by means values with standard deviations. Dose response curves were established for chemicals at concentrations where they do not modulate luciferase expression in the HG5LN control cell line. Curves were modelled based on the four parameters hill equation using the freely available Excel Macro REGTOX 7.02 (18). This allowed to determine EC50 and IC50 values of tested chemicals.

**RESULTS**

**Modulation of the Transcriptional Activity of the zf and hPXR by Various Chemicals**
In this study, we evaluated the ability of PXR prototypical ligands, 21 steroids and 80 pesticides (Supplementary Table 1), to modulate both zfPXR and hPXR. The chemicals were first tested for non-specific modulation of luciferase expression on the HG5LN parental cell line, which contains the same reporter gene as HG5LN-GAL4-PXRs cells, but lacks Gal4-PXRs (data not shown). Then the chemicals were tested on the HG5LN GAL4-hPXR and GAL4-zfPXR at concentrations that were not able to inhibit or activate luciferase expression in the HG5LN reporter cell line.

The activity of the chemicals on hPXR was compared to the activity of the reference PXR agonist SR12813. This compound fully activated hPXR with an EC50 of 0.16 µM while it was not active in the HG5LN Gal-zfPXR cells (Figure 1A and Table 1).

Rifampicin, another well-characterized hPXR full agonist, was also found exclusively active on hPXR with an EC50 of 0.44 µM (Table 1). For zfPXR, the activity of the chemicals was compared to the activity of the reference ligand clotrimazole. This compound activated both the HG5LN Gal-zfPXR and Gal-hPXR cell lines with the half-maximal effective concentration (EC50) values of 0.03 µM and 1.0 µM respectively (Figure 1B and Table 1). SPA70 (20) and econazole nitrate were used as reference antagonists for hPXR and zfPXR, respectively. SPA70 inhibited only hPXR, with an IC50 of 0.41 µM (Figure 1C and Table 1). Econazole nitrate inhibited luciferase activity in HG5LN Gal-zfPXR whereas it activated it in HG5LN Gal-hPXR cell lines. The EC50 for hPXR was 12 µM and the IC50 for zfPXR was 2.8 µM (Figure 1D and Table 1). Finally, pregnenolone 16α-carbonitrile, a mouse PXR agonist, partially activated hPXR whereas it did not activate zPXR. Dexamethasone, another mouse PXR agonist, had no effect on hPXR and zPXR.

We evaluated the ability of 21 progestins to modulate both hPXR and zPXR (Table 2). Among them, 9 modulated the activity of hPXR whereas 11 modulated that of zfPXR. All the active steroids on hPXR were agonists with EC50 values comprised between 4.2 µM (desogestrel) and 41 µM (lynestrenol) (Figure 2A and Table 2). On zfPXR, 8 steroids were agonists of the zfPXR with EC50 values between 0.13 µM (desogestrel) and 2.3 µM (etonogestrel) (Figure 2B and Table 2). Surprisingly, 3 steroids were antagonists of the zfPXR with IC50 values comprised between 0.08 µM (mifepristone) and 3.6 µM (drosiprenone) (Figure 2C and Table 2). These results indicate that progestins have a preferential selectivity for zfPXR rather than hPXR and that zfPXR is more prone to be antagonized than hPXR.

We then evaluated the ability of 80 pesticides to modulate both zfPXR and hPXR (Table 3). Among them, 61 modulated the activity of hPXR whereas 49 modulated that of zfPXR. All the active pesticides on hPXR were agonists with EC50 values comprised between 0.18 µM (pretetachlor) and 39 µM (vinclozolin M2) (Table 2). On zfPXR, 38 were agonists and 11 were antagonists. The most potent zPXR agonist was toxaphene (0.15 µM) (Figure 3B and Table 2) whereas deltamethrin and cypermethrin were the most potent antagonists (Figures 3C, D and Table 2). These results indicate that pesticides have a preferential selectivity for hPXR rather than zfPXR and that again zfPXR is more easily antagonized than hPXR.

To confirm the zfPXR activity of the chemicals in a zebrafish cellular context, we established a zfPXR zebrafish reporter cell line. We stably cotransfected the zebrafish hepatoma cells ZFL with a pS75-zfPXR-puromycin and a PXRE6-TATA-luciferase-hygromycine plasmid. In these cells, we tested some of the most active zfPXR agonists and antagonists. EC50s obtained in ZFL-zfPXR cells (0.02, 0.07 and 0.12 µM for clotrimazole, desogestrel and pendimethalin, respectively) were in the same range of those obtained in HG5LN GAL4-zfPXR cells (0.03, 0.13 and 0.47 µM for clotrimazole, desogestrel and pendimethalin, respectively) (Figure 4A and Table 4). Similarly, IC50s obtained ZFL-zfPXR
cells (0.90, 0.06 and 1.6 µM for econazole nitrate, mifepristone and deltamethrin, respectively) are in the same range of those obtained in HG5LN GAL4-zfPXR cells (2.8, 0.08 and 1.6 µM for econazole nitrate, mifepristone and deltamethrin, respectively) (Figure 4B and Table 4).

**Structural Analysis of zfPXR Selectivity**

To gain structural insights into zfPXR ligand binding selectivity, we generated a model of zfPXR LBD using the web-based server EDMon (Endocrine Disruptor Monitoring; http://edmon.cbs.cnrs.fr) (21, 22), and superposed it on the experimental crystal.

---

**TABLE 1 | Maximal or minimal activity and EC50 or IC50 of reference compounds on HG5LN-hPXR and HG5LN-zfPXR.**

| Compound                    | hPXR agonism | zfPXR agonism | zfPXR antagonism |
|-----------------------------|--------------|---------------|------------------|
|                             | EC50 (µM)    | Max (%)       | EC50 (µM)        | Max (%)       | IC50 (µM) | Min (%) |
| DMSO                        |              | 19 ± 6        | 28 ± 1.7         |               |           |         |
| Clotrimazole*               | 1.0 ± 0.1    | 59            | 0.03 ± 0.002     | 100           | n.a.      | -       |
| Econazole nitrate           | 12 ± 3.0     | 51            | n.a.             | -             | 2.8 ± 0.1 | 16      |
| SR12813                     | 0.16 ± 0.01  | 100           | n.a.             | -             | n.a.      | -       |
| Rifampicin                  | 0.44 ± 0.03  | 74            | n.a.             | -             | n.a.      | -       |
| SPA70*                      | 0.41 ± 0.04  | 14            | n.a.             | -             | n.a.      | -       |
| Pregnenolone 16α-carbonitrile| 22 ± 9.7     | 32            | n.a.             | -             | n.a.      | -       |
| Dexamethasone               | n.a.         | -             | n.a.             | -             | n.a.      | -       |

n.a., not active; max, maximal activity of the chemicals obtained at 10 µM except for compounds that were not tested above 3 µM because of toxicity; min, minimal activity of the chemicals obtained at 10 µM except for compounds that were not tested above 3 µM because of toxicity.*

Maximal activities of the chemicals obtained at 10 µM (excepted for clotrimazole which was tested at the maximal concentration of 1 µM) are expressed as a percentage of the maximal induced by 3 µM SR 12813 and 1 µM clotrimazole for HG5LN-hPXR and HG5LN-zfPXR, respectively. Antagonism assays were performed in coexposure with 0.3 µM SR 12813 in HG5LN-hPXR cells and 0.03 µM clotrimazole in HG5LN-zfPXR cells. Minimal activities of the chemicals obtained at 10 µM (excepted for SPA70 which was tested at the maximal concentration of 1 µM) are expressed as a percentage of the maximal induced by 3 µM SR 12813 and 1 µM clotrimazole for HG5LN-hPXR and HG5LN-zfPXR, respectively.

---

* FIGURE 1 | Transcriptional activity of hPXR and zfPXR in response to reference chemicals SR 12813 (A), clotrimazole (B), SPA 70 (C), and econazole nitrate (D). Results are expressed as a percentage of the maximum luciferase activity induced by 3 µM SR 12813 (HG5LN-hPXR) or 1 µM clotrimazole (HG5LN-zfPXR). Error bars represent standard deviations.
TABLE 2 | Maximal or minimal activity and EC50 or IC50 of progestins on HG5LN-hPXR and HG5LN-zfPXR.

| Compound                          | hPXR agonism | zfPXR agonism | zfPXR antagonism |
|-----------------------------------|--------------|---------------|-----------------|
|                                   | EC50 (µM)    | Max (%)       | EC50 (µM)       | Max (%)       | IC50 (µM)     | Min (%)       |
| DMSO                              |              |               | 19 ± 6          |              | 28 ± 1.7      |               |
| Chlormadinone acetate             | n.a.         | -             | n.a.            | -            | n.a.         | -             |
| Desogestrel*                      | 4.2 ± 0.2    | 54            | 0.13 ± 0.01     | 99           | n.a.         | -             |
| 17α,20β-Dihydroxy-4-pregnen-3-one | n.a.         | -             | n.a.            | -            | n.a.         | -             |
| Drospirenone                      | 18 ± 1.4     | 44            | n.a.            | -            | 3.6 ± 0.4    | 52            |
| Dydrogesterone                    | n.m.         | 27            | n.a.            | -            | n.a.         | -             |
| Ethisterone                       | n.a.         | -             | n.a.            | -            | n.a.         | -             |
| Elyniod diacetate*                | n.a.         | -             | 0.32 ± 0.02     | 92           | n.a.         | -             |
| Etonogestrel                      | 24 ± 4.6     | 27            | 2.3 ± 0.2       | 90           | n.a.         | -             |
| Gestodene*                        | n.a.         | -             | 0.18 ± 0.01     | 81           | n.a.         | -             |
| Gestonorone                       | n.a.         | -             | n.a.            | -            | n.a.         | -             |
| Levonorgestrel                    | n.a.         | -             | 1.4 ± 0.2       | 74           | n.a.         | -             |
| Lynestrenol*                      | 41 ± 7.7     | 30            | 0.23 ± 0.01     | 98           | n.a.         | -             |
| Medroxyprogesterone               | 18 ± 2.4     | 50            | n.a.            | -            | n.a.         | -             |
| Megestrol acetate                 | 19 ± 4.3     | 50            | n.a.            | -            | n.a.         | -             |
| Mifepristone*                     | 5.9 ± 0.2    | 39            | n.a.            | -            | 0.08 ± 0.003 | 10            |
| Nestorone                         | n.a.         | -             | n.a.            | -            | n.a.         | -             |
| Nomegestrol acetate               | n.a.         | -             | n.a.            | -            | n.a.         | -             |
| Norethisterone                    | n.a.         | -             | 2.2 ± 0.4       | 54           | n.a.         | -             |
| Progesterone                      | 9.1 ± 2.2    | 72            | n.a.            | -            | 0.64 ± 0.03  | 14            |
| Promegestone                      | n.a.         | -             | n.a.            | -            | n.a.         | -             |
| Tibolone*                         | n.a.         | -             | 0.56 ± 0.04     | 96           | n.a.         | -             |

n.a., not active; max, maximal activity of the chemicals obtained at 10 µM except for compounds that were not tested above 3 µM because of toxicity*; min, minimal activity of the chemicals obtained at 10 µM except for compounds that were not tested above 3 µM because of toxicity*.

Maximal activities of the chemicals obtained at 10 µM are expressed as a percentage of the maximal induced by 3 µM SR 12813 and 1 µM clotrimazole for HG5LN-hPXR and HG5LN-zfPXR, respectively. Antagonism assays were performed in coexposure with 0.3 µM SR 12813 in HG5LN-hPXR cells and 0.03 µM clotrimazole in HG5LN-zfPXR cells. Minimal activities of the chemicals obtained at 10 µM are expressed as a percentage of the maximal induced by 3 µM SR 12813 and 1 µM clotrimazole for HG5LN-hPXR and HG5LN-zfPXR, respectively.

FIGURE 2 | Transcriptional activity of hPXR and zfPXR in response to steroids. (A) Agonist steroids on HG5LN-hPXR; (B) Agonist steroids on HG5LN-zfPXR; (C) Antagonist steroids on HG5LN-zfPXR. Results are expressed as a percentage of the maximum luciferase activity induced by 3 µM SR 12813 (HG5LN-hPXR) or 1 µM clotrimazole (HG5LN-zfPXR). Error bars represent standard deviations.
| Compound                  | hPXR agonism | zfPXR agonism | zfPXR antagonism | Compound                  | hPXR agonism | zfPXR agonism | zfPXR antagonism |
|---------------------------|--------------|---------------|------------------|---------------------------|--------------|---------------|------------------|
| **EC50 (µM) Max (%)**     |              |               |                  | **EC50 (µM) Max (%)**     |              |               |                  |
| DMSO                      | 19 ± 6       | 28 ± 1.7      | n.a.             | DMSO                      | 19 ± 6       | 28 ± 1.7      | n.a.             |
| 2,4-DDE                   | 5.5 ± 0.4    | 78            | n.m.             | Heptachlor endo-epoxide*  | 3.4 ± 0.7    | 69            | 2.0 ± 0.9        |
| 4,4'-DDE                  | 5.6 ± 0.3    | 77            | n.a.             | Heptachlor exo-epoxide*  | 1.9 ± 0.1    | 85            | 1.4 ± 0.44       |
| Alachlor                  | 1.5 ± 0.4    | 76            | 0.67 ± 0.10      | Hexachlorobenzene         | n.a.         | n.a.          | n.a.             |
| Aldicarb                  | 7.6 ± 0.3    | 70            | 10 ± 4.5         | HPTE                      | n.a.         | 1.8 ± 0.44    | 37               |
| Aldrin                    | n.a.         | n.a.          | n.a.             | Imaizyl*                  | 10 ± 1.4     | 39            | 9.8 ± 2.6        |
| Azimsulfuron              | n.a.         | n.a.          | n.a.             | Lindane*                  | 10 ± 1.8     | 62            | 14 ± 0.9         |
| Bifenox                   | 4.5 ± 0.7    | 84            | 5.5 ± 0.4        | Linuron                   | 29 ± 3.2     | 40            | n.a.             |
| Bifenthrin                | 13 ± 1.1     | 55            | 58 ± 82          | Mecoprop                  | n.a.         | n.a.          | n.a.             |
| Bupirimate*              | 1.7 ± 0.1    | 101           | 22 ± 5.1         | Metaluyl                  | 31 ± 2.6     | 40            | 20 ± 3.1         |
| Captan*                  | n.a.         | n.a.          | n.a.             | Metamitron                | n.a.         | n.a.          | n.a.             |
| Chlordecone*             | 19 ± 5.6     | 46            | 75 ± 23          | Methoxychlor*             | 17 ± 1.7     | 49            | n.a.             |
| Chlorfenuron             | n.a.         | n.a.          | n.a.             | Metolachlor               | 0.68 ± 0.07  | 69            | 0.63 ± 0.03      |
| Chlorpropham*            | 20 ± 8.6     | 49            | 22 ± 16          | Mirex                     | n.a.         | n.a.          | n.a.             |
| Chlorpyrifos*            | 2.7 ± 0.4    | 95            | 3.0 ± 0.3        | Nicosulfuron              | n.a.         | n.a.          | n.a.             |
| Chlorpyrifos*            | 2.7 ± 0.4    | 95            | 3.0 ± 0.3        | Nicosulfuron              | n.a.         | n.a.          | n.a.             |
| Chlorothalon              | 7.6 ± 0.3    | 70            | 10 ± 4.5         | Nicoumarol                | n.a.         | n.a.          | n.a.             |
| Chlordane*               | 7.4 ± 3.8    | 82            | 73 ± 22          | Oxadiazon                 | 1.1 ± 0.0001 | 76            | n.a.             |
| Cis-chlordane*           | 8.6 ± 3.0    | 87            | 13 ± 0.4         | Oxychloridane             | 4.3 ± 0.3    | 69            | n.a.             |
| Cis-nonachlor*           | 7.4 ± 3.8    | 82            | 73 ± 22          | Oxyfluorfen               | 3.0 ± 0.1    | 86            | 10 ± 1.2         |
| Lambda-Cyhalothrin       | 1.7 ± 0.2    | 107           | n.a.             | 6.8 ± 1.0                 | 45           | n.a.          | 1.5 ± 0.1        |
| Cypromethrin             | 1.8 ± 0.2    | 100           | n.a.             | Benfenthrin               | 1.9 ± 0.2    | 98            | n.a.             |
| Cyproconazole             | 1.8 ± 0.2    | 92            | 1.6 ± 0.2        | Bifenthrin                | 3.0 ± 0.1    | 91            | 0.47 ± 0.1       |
| Deltamethrin             | 9.2 ± 1.4    | 62            | n.a.             | Bifenthrin*               | 22 ± 33      | 69            | 1.1 ± 0.1        |
| Diclofop-methyl          | 1.7 ± 0.2    | 76            | 0.70 ± 0.21      | Bifenthrin*               | 11 ± 0.3     | 59            | 2.5 ± 0.1        |
| Dieldrin*               | 7.6 ± 0.3    | 70            | 10 ± 4.5         | Bifenthrin*               | 11 ± 0.3     | 59            | 2.5 ± 0.1        |
| Diafenthenoxuron         | 19 ± 2.4     | 45            | n.a.             | Bifenthrin*               | n.a.         | n.a.          | n.a.             |
| Diuron                   | n.a.         | n.a.          | n.a.             | Bifenthrin*               | n.a.         | n.a.          | n.a.             |
| Endosulfan               | 5.7 ± 0.4    | 72            | 11 ± 1.5         | Bifenthrin*               | n.a.         | n.a.          | n.a.             |
| Endrin*                 | 6.9 ± 1.2    | 76            | 14 ± 1.2         | Bifenthrin*               | n.a.         | n.a.          | n.a.             |
| Epoxiconazole            | 8.1 ± 0.2    | 72            | 1.6 ± 0.1        | Bifenthrin*               | n.a.         | n.a.          | n.a.             |
| Ethoprophos              | 8.1 ± 0.2    | 72            | 1.6 ± 0.1        | Bifenthrin*               | n.a.         | n.a.          | n.a.             |
| Etofenprox               | 3.0 ± 0.2    | 81            | n.a.             | Bifenthrin*               | 35 ± 7.3     | 46            | n.a.             |
| Fenamiphos               | 1.7 ± 0.2    | 76            | 0.70 ± 0.21      | Bifenthrin*               | 11 ± 0.3     | 59            | 2.5 ± 0.1        |
| Fenfluraxone             | 13 ± 2.2     | 56            | n.a.             | Bifenthrin*               | 11 ± 0.3     | 59            | 2.5 ± 0.1        |
| Fenbuconazole*           | 32 ± 13      | 43            | n.m.             | Bifenthrin*               | 4.3 ± 0.3    | 92            | 16 ± 0.8         |
| Fenvarlate*              | 1.7 ± 0.05   | 79            | n.a.             | Bifenthrin*               | 5.3 ± 0.2    | 70            | 29 ± 5.5         |
| Fipronil                 | 5.4 ± 0.4    | 73            | n.a.             | Bifenthrin*               | 21 ± 14      | 51            | 6.0 ± 0.8        |
| Fipronil sulfone*        | 4.4 ± 0.4    | 73            | n.a.             | Bifenthrin*               | 39 ± 9.6     | 35            | n.a.             |
| Flufenoxuron*            | 5.4 ± 0.4    | 73            | n.a.             | Bifenthrin*               | n.a.         | n.a.          | n.a.             |
| Fluvilinate              | 11 ± 0.1     | 74            | n.a.             | Bifenthrin*               | n.a.         | n.a.          | n.a.             |
| Heptachlor               | 4.4 ± 0.4    | 73 ± 1.8      | 44 n.a.          | Bifenthrin*               | n.a.         | n.a.          | n.a.             |
| n.a., not active; n.m., not modelable; max, maximal activity of the chemicals obtained at 10 µM except for compounds that were not tested above 3 µM because of toxicity or non-specificity*; min, minimal activity of the chemicals obtained at 10 µM except for compounds that were not tested above 3 µM because of toxicity or non-specificity*. Maximal activities of the chemicals obtained at 10 µM are expressed as a percentage of the maximal induced by 3 µM SR 12813 and 1 µM clotrimazole for HG5LN-hPXR and HG5LN-zfPXR, respectively. Antagonism assays were performed in coexposure with 0.3 µM SR 12813 in HG5LN-hPXR cells and 0.03 µM clotrimazole in HG5LN-zfPXR cells. Minimal activities of the chemicals obtained at 10 µM are expressed as a percentage of the maximal induced by 3 µM SR 12813 and 1 µM clotrimazole for HG5LN-hPXR and HG5LN-zfPXR, respectively.

**Creusot et al. Human and Zebrafish PXR Activation**

*Frontiers in Endocrinology | www.frontiersin.org May 2021 | Volume 12 | Article 6655216*
structures of hPXR in complex with SR12813 (23) and clotrimazole (16). As previously observed, the ligand-binding pockets (LBP) of hPXR and zfPXR show significant differences in their size and residue composition (7, 8). In a recent study on the human receptor, we observed that PXR contains an aromatic cage deeply buried at the bottom of the LBP and made up of residues F288, W299 and Y306. This unique aromatic triad (referred to as the \( \pi \)-trap) catches compounds through their most hydrophobic moieties and constitutes the main anchoring point of many compounds, including clotrimazole (16). Interestingly, residues forming the \( \pi \)-trap are fully conserved in zfPXR (Figure 5). However, a number of more or less drastic residue substitutions distributed all over the LBPs modulate the interactions between PXR orthologs and chemicals, and account for the differential ligand selectivity of both receptor species. As an example, Figure 5A shows how hPXR is able to accommodate SR12813 with strong affinity, while, in contrast, a steric hindrance generated by the replacement of several methionine and histidine residues from helices H3, H11 and H12 by larger and less flexible amino acids prevents binding of SR12813 to the fish receptor. On the contrary, zfPXR is able to accommodate the smaller compound clotrimazole, essentially \( \pi \)-trap interaction with the conserved \( \pi \)-trap. Additional contacts with zfPXR-specific residues such as F239, I280, L281 (not shown) and Y404 may explain the significantly higher affinity of this compound for the fish receptor (Figure 5B).

**DISCUSSION**

In the present study, we evaluated the ability of 21 progestins and 80 pesticides to alter the transcriptional activity of both zfPXR and hPXR. In accordance with previous studies (8, 24, 25), our data confirmed that clotrimazole is the most potent ligand of the zfPXR (EC50 of 0.03 µM), as in other fish species (6, 7). Clotrimazole also activates hPXR but with a lower potency.

Our data also confirmed that the pharmaceuticals SR12813 and rifampicin (hPXR ligands) do not modulate zfPXR as previously reported for carp and zebrafish receptors (6, 8, 10, 25). This observation is in contrast with gene expression studies in carp (4) and zebrafish (26) showing that CYP3A65, a suspected target gene of the fish PXR, is upregulated by rifampicin in these species.

We showed that the modulation of the zfPXR by progestins occurs at lower concentrations than the hPXR modulation. Ekins et al. (8) have previously compared zfPXR and hPXR transactivation by numerous steroids (i.e., estranes, androstanes, pregnanes) and reported a lower promiscuity of the zfPXR (EC50 of 0.03 µM), as in other fish species (6, 7). Clotrimazole also activates hPXR but with a lower potency.

Our study indicates that for progestins, zfPXR is more promiscuous than hPXR. A study including a larger selection of steroids will be necessary to confirm that among steroids, progestins present a
zfPXR selectivity. Crystallization of zfPXR in complex with steroids and mutagenesis of the main amino acids in contact with the steroids in the zfPXR pocket would enable to confirm this selectivity. We also showed that the synthetic glucocorticoid dexamethasone and the pregnane pregnenolone 16α-carbonitrile, which are mouse PXR agonists, do not modulate zfPXR in accordance with what was previously reported with carp and zebrafish receptors (6, 8, 27).

Our data also confirmed the low promiscuity of the zfPXR to pesticides compared to hPXR, as previously reported (7, 8, 27). Such discrepancies were also observed in the carp (6) and in the rainbow trout (28). Although less pesticides modulated the zfPXR, we highlighted that the zfPXR was sensitive to some of these contaminants. In particular, clotrimazole was able to modulate zfPXR at low concentrations.

Importantly, out of the 105 chemicals tested (4 reference chemicals, 80 pesticides and 21 progestins), 15 acted as antagonists of the zfPXR while none of them were identified as hPXR antagonists. Moreover, some agonists of the hPXR like mifepristone and econazole nitrate acted as antagonists of the zfPXR. To our knowledge, this study is the first to report the ability of organic chemicals, including environmental contaminants, to negatively regulate the transcriptional activity of a fish PXR. Note in this respect that the first fully validated competitive inhibitors of hPXR have been reported only recently (20, 29). Overall, some of the specific structural features of hPXR (e.g. large LBP size and high plasticity) most likely account for its

| TABLE 4 | Maximal or minimal activity and EC50 or IC50 of chemicals on ZFL-zfPXR. |
| Compound | zfPXR agonism | zfPXR antagonism |
| Compounds | EC50 (µM) | Max (%) | IC50 (µM) | Min (%) |
| DMSO | 25 ± 2.3 | 100% | n.a. | - |
| Clotrimazole* | 0.02 ± 0.002 | 100 | n.a. | - |
| Desogestrel* | 0.07 ± 0.004 | 98 | n.a. | - |
| Pendimethalin | 0.12 ± 0.01 | 92 | n.a. | - |
| Econazole nitrate | n.a. | - | 0.90 ± 0.05 | 2 |
| Mifepristone* | n.a. | - | 0.06 ± 0.004 | 5 |
| Deltamethrin | n.a. | - | 1.6 ± 0.06 | 3 |

n.a., not active; max, maximal activity of the chemicals obtained at 10 µM except for compounds that were not tested above 3 µM because of toxicity or non-specificity*; min, minimal activity of the chemicals obtained at 10 µM except for compounds that were not tested above 3 µM because of toxicity or non-specificity*.

Maximal activities of the chemicals obtained at 10 µM are expressed as a percentage of the maximal induced by 1 µM clotrimazole. Antagonism assays were performed in coexposure with 0.03 µM clotrimazole. Minimal activities of the chemicals obtained at 10 µM are expressed as a percentage of the maximal induced by 3 µM SR 12813 and 1 µM clotrimazole for HG5LN-hPXR and HG5LN-zfPXR, respectively.
refractoriness to antagonism (16, 30), while in contrast, the smaller and less malleable zPXR LBP (17) could explain why the zebrafish receptor is more prone to antagonism. Notably, the substitution of a comfortable methionine residue in helix H12 of hPXR for a bulky and rigid tryptophan residue in zPXR (Figure 5) may enable easier destabilization of the active conformation of the activation helix by chemicals. Again, crystallization of zPXR in complex with RU486 or other zPXR antagonists would considerably improve our understanding of the mechanism of inhibition of zPXR.

In human, there is an increasing concern regarding adverse PXR-dependent drug interactions that may be well avoided with suitable PXR antagonists. Recently Chen and coworkers (20, 29) have succeeded to identify a selective and potent hPXR antagonist, SPA70. They failed to crystallize hPXR in complex with SPA70 but succeeded to crystallize hPXR with the chemical SJ7, an agonist closely related to SPA70. The amino acids M425, L428 and F429 from H12 sequence interact with SJ7 and stabilize H12 into an active conformation. Using modelling, Huber et al. (31) proposed that SPA70 fails to stabilize H12 for co-activator binding due to loss of interactions with L428 and F429 (31).

Overall, the promiscuity of PXRs suggests a major role of this receptor in protection of an individual against toxic levels of exogenous (i.e., xenobiotics) and endogenous compounds (hormones, bile salts). From an evolutionary standpoint, the current challenge is to decipher why this receptor has such striking cross-species sequence variation in the LBD and even in ligand-binding residues across mammalian and non-mammalian species (32). This suggests that key ligands of PXR vary across species due to differences either in diet or in physiology. The present study showed that zPXR is modulated by a variety of ligands but with a lower promiscuity than the hPXR. In particular, it was mainly modulated by progestins. In conclusion, the current study evaluated differences in the activation or inhibition of human and zebrafish PXR by progestins and pesticides and highlighted strong species-specific differences. Furthermore, we observed in a recent study that water extracts could induce different responses in hPXR and zPXR (19) confirming that these receptors are differently activated by environmental chemicals. Altogether, these results indicate that zebrafish nuclear receptor assays should be preferred over human nuclear receptor assays to evaluate the potential risks posed by endocrine-disrupting chemicals to aquatic organisms.

DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

AUTHOR CONTRIBUTIONS
PB designed research. NC, CG, MG, and WB performed research. AB and BC contributed with new reagents/analytic tools. NC, CG, WB, and PB analyzed data. and NC, CG, WB, and PB wrote the paper. All authors contributed to the article and approved the submitted version.

FUNDING
We acknowledge financial support from the French Agency for Food, Environmental and Occupational Health & Safety projects TOXCHEM: N°2018/1/020 (PNR EST) (to PB and WB), the Programme National de Recherche sur les Perturbateurs Endocriniens PestR (PB and WB), and SYNEPEST (PB).

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2021.665521/full#supplementary-material

REFERENCES
1. Wang YM, Ong SS, Chai SC, Chen T. Role of CAR and PXR in Xenobiotic Sensing and Metabolism. Expert Opin Drug Metab Toxicol (2012) 8:803–17. doi: 10.1517/17425255.2012.685237
2. Pondugula S R, Pavek P, Mani S. Pregnane X Receptor and Cancer: Context-Specificity is Key. Nucl Recept Res (2016) 3:101198. doi: 10.11131/2016/101198
3. Chang CT, Chung HY, Su HT, Tseng HP, Tzou WS, Hu CH. Regulation of Zebrafish CYP3A65 Transcription by AHR2. Toxicol Appl Pharmacol (2013) 270:174–84. doi: 10.1016/j.taap.2013.04.010
4. Corcoran J, Lange A, Cumming RJ, Owen SF, Ball JS, Tyler CR, et al. Bioavailability of the Imidazole Antifungal Agent Clotrimazole and its Effects on Key Biotransformation Genes in the Common Carp (Cyprinus Carpio). Aquat Toxicol (2014) 152:57–65. doi: 10.1016/j.aquatox.2014.03.016
5. Kubota A, Goldstone JV, Lemaire B, Takata M, Woodin BR, Stegeman JJ. Role of Pregnane X Receptor and Aryl Hydrocarbon Receptor in Transcriptional Regulation of Pxr, CYP2, and CYP3 Genes in Developing Zebrafish. Toxicol Sci (2015) 143:398–407. doi: 10.1093/toxsci/kfu240
6. Lange A, Corcoran J, Miyagawa S, Iguchi T, Winter MJ, Tyler CR. Development of a Common Carp (Cyprinus Carpio) Pregnane X Receptor (Cpxr) Transactivation Reporter Assay and its Activation by Azole Fungicides and Pharmaceutical Chemicals. Toxicol Vitr (2017) 41:114–22. doi: 10.1016/j.tiv.2017.02.023
7. Milnes MR, Garcia A, Grossman E, Grün F, Shiotsugu J, Tabb MM, et al. Activation of Steroid and Xenobiotic Receptor (SXR, NR1/2) and its Orthologs in Laboratory, Toxicologic, and Genome Model Species. Environ Health Perspect (2008) 116:880–5. doi: 10.1289/ehp.10853
8. Ekins S, Rechly EJ, Hagey LR, Krasowski MD. Evolution of Pharmacologic Specificity in the Pregnane X Receptor. BMC Evol Biol (2008) 8:163. doi: 10.1186/1471-2148-8-103
9. Kliwer SA, Goodwin B, Wilson TM. The Nuclear Pregnane X Receptor: A Key Regulator of Xenobiotic Metabolism. Endocr Rev (2002) 23:687–702. doi: 10.1210/er.2001-0038
10. Creusot N, Kinani S, Balaguer P, Tapie N, Lermenach K, Mailiot-Maréchal E, et al. Evaluation of an Hpr Reporter Gene Assay for the Detection of Aquatic Emerging Pollutants: Screening of Chemicals and Application to Water Samples. *Analyt Bioanalyt Chem* (2010) 398(2):569–83. doi: 10.1007/b0026-009-3510-y

11. Grimaldi M, Boulahtouf A, Toporova L, Balaguer P. Functional Profiling of Bisphenol for Nuclear Receptors. *Toxicology* (2019) 420:39–45. doi: 10.1016/j.tox.2019.04.003

12. Kojima H, Sata F, Takeuchi S, Sueyoshi T, Nagai S. Comparative Study of Human and Mouse Pregnane X Receptor Agonistic Activity in 200 Pesticides Using *In Vitro* Reporter Gene Assays. *Toxicology* (2011) 280:77–87. doi: 10.1016/j.tox.2011.11.008

13. Kojima H, Takeuchi S, Sanoh S, Okada K, Kitamura S, Uramaru N, et al. Profiling of Bisphenol a and Eight Its Analogues on Transcriptional Activity Via Human Nuclear Receptors. *Toxicology* (2019) 413:48–55. doi: 10.1016/j.tox.2018.12.001

14. Lemaire G, Mif W, Pascussi JM, Pillon A, Rabenoelina F, Fenet H, et al. Identification of New Human Pregnane X Receptor Ligands Among Pesticides Using a Stable Reporter Cell System. *Toxicol Sci* (2006) 91:501–9. doi: 10.1093/toxsci/kfl173

15. Defosse V, Dendele B, Huet T, Grimaldi M, Boulahtouf A, Gerbal-chaloin S, et al. Synergetic Activation of Human Pregnan X Receptor by Binary Cocktails of Pharmaceuticals and Environmental Compounds. *Nat Commun* (2015) 6:8089. doi: 10.1038/ncomms9089

16. Defosse V, Huet T, Harrus D, Granell M, Bourguet M, Gardia-Parège C, et al. Mechanistic Insights Into the Synergistic Activation of the RXR–PXR Heterodimer by Endocrine Disruptor Mixtures. *Proc Natl Acad Sci USA* (2021) 118(1):e2020551118. doi: 10.1073/PNAS.2020551118

17. Krasowski MD, Ai N, Hagey LR, Kollitz EM, Kullman SW, Reschly EJ, et al. The Evolution of Farnesoid X, Vitamin D, and Pregnane X Receptors: Insights From the Green-Spotted Pufferfish (Tetraodon Nigriviridis) and Other Non-Mammalian Species. *BMC Biochem* (2011) 12:5. doi: 10.1186/1471-2091-12-5

18. Vindimian E. MSExcel Macro Regto x 7.02 Freely available from Eric Vindimian. IRSTEA, France (2012). Available at: http://www.normalesup.fi

19. Neale PA, Grimaldi M, Boulahtouf A, Leusch FDL, Balaguer P. Assessing Species-Specific Differences for Nuclear Receptor Activation for Environmental Water Extracts. *Water Res* (2020) 185:116247. doi: 10.1016/j.watres.2020.116247

20. Lin W, Wang Y, Chai SC, Lv L, Zheng J, Wu J, et al. SPA70 is a Potent Antagonist of Human Pregnan X Receptor. *Nat Commun* (2017) 8:741. doi: 10.1038/ncomms14467-017-00780-5

21. Schneider M, Pons JL, Labesse G, Bourguet W. In Silico Predictions of Endocrine Disruptors Properties. *Endocrinology* (2019) 160:2709–18. doi: 12.1016/en.2019-00382

22. Schneider M, Pons JL, Bourguet W, Labesse G. Towards Accurate High-Throughput Ligand Affinity Prediction by Exploiting Structural Ensembles, Docking Metrics and Ligand Similarity. *Bioinformatics* (2020) 36:160–8. doi: 10.1093/bioinformatics/btz538

23. Watkins RE, Davis-Seales PR, Lambert MH, Redinho MR. Coactivator Binding Promotes the Specific Interaction Between Ligand and the Pregnane X Receptor. *J Mol Biol* (2003) 331:815–28. doi: 10.1016/S0022-2836(03)00795-2

24. Bainy AC, Kubota A, Goldstone JV, Lille-Langoy R, Karchner SJ, Celander MC, et al. Functional Characterization of a Full Length Pregnane X Receptor, Expression in Vivo, and Identification of PXR Alleles, in Zebrafish (*Danio Rerio*). *Aquat Toxicol* (2013) 142–143:447–57. doi: 10.1016/j.aquatox.2013.09.014

25. Moore LB, Parks DJ, Jones SA, Bledsoe RK, Consler TG, Stimmel JB, et al. Orphan Nuclear Receptors Constitutive Androstane Receptor and Pregnane X Receptor Share Xenobiotic and Steroid Ligands. *J Biol Chem* (2000) 275:15122–7. doi: 10.1074/jbc.M001215200

26. Tseng HP, Hseu TH, Buhler DR, Der WW, Hu CH. Constitutive and Xenobiotics-Induced Expression of a Novel CYP3A Gene From Zebrafish Larva. *Toxicol Appl Pharmacol* (2005) 205:247–58. doi: 10.1016/j.taap.2004.10.019

27. Moore LB, Maglich JM, Mckee DD, Wisely B, Willson TM, Kliwer SA, et al. Pregnane X Receptor (PXR), Constitutive Androstane Receptor (CAR), and Benzoxo X Receptor (BXR) Define Three Pharmacologically Distinct Classes of Nuclear Receptors (2002). Available at: https://academic.oup.com/mend/article-abstract/16/5/977/2741668 (Accessed July 13, 2020).

28. Wassmu B, Gräns J, Kling P, Celander MC. Interactions of Pharmaceuticals and Other Xenobiotics on Hepatic Pregnane X Receptor and Cytochrome P450 3A Signaling Pathway in Rainbow Trout (*Oncorhynchus Mykiss*). *Aquat Toxicol* (2010) 100:91–100. doi: 10.1016/j.aquatox.2010.07.013

29. Li Y, Lin W, Wright WC, Chai SC, Wu J, Chen T. Building a Chemical Toolbox for Human Pregnane X Receptor Research: Discovery of Agonists, Inverse Agonists, and Antagonists Among Analogs Based on the Unique Chemical Scaffold of SPA70. *J Med Chem* (2021) 64(3):1733–61. doi: 10.1021/acs.jmedchem.0c02201

30. Chai SC, Wright WC, Chen T. Strategies for Developing Pregnane X Receptor Antagonists: Implications From Metabolism to Cancer. *Med Res Rev* (2020) 40:1061–83. doi: 10.1002.med.21648

31. Huber AD, Wright WC, Lin W, Majumder K, Low JA, Wu J, et al. Mutation of a Single Amino Acid of Pregnane X Receptor Switches an Antagonist to Agonist by Altering AF-2 Helix Positioning. *Cell Mol Life Sci* (2020) 78(1):317–35. doi: 10.1007/s00018-020-03505-y

32. Reschly E, Krasowski M. Evolution and Function of the NR1I Nuclear Receptor Subfamily (VDR, PXR, and CAR) With Respect to Metabolism of Xenobiotics and Endogenous Compounds. *Curr Drug Metab* (2006) 7:349–65. doi: 10.2174/138920006776873526

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.